Comparative evaluation of the efficacy of itraconazole with terbinafine cream versus itraconazole with sertaconazole cream in dermatophytosis: A within person pilot study

BackgroundCurrent trend of rising drug-resistant dermatophyte infection is alarming and fretted by dermatologists. Dilemma prevails regarding use of the same or different class of antifungal agents topically and systemically. The aim was to study the efficacy of oral itraconazole 200 mg with 1% terbinafine cream versus oral itraconazole 200 mg with 2% sertaconazole cream in dermatophytosis.MethodsThis within-person open-label pilot study enrolled 50 patients with dermatophytosis. Two lesions of comparable size within each patient were randomly allotted to group A and B and treated with 2% sertaconazole and 1% terbinafine cream, respectively. Both groups received itraconazole 200 mg once daily for 4 weeks. The remaining lesions received 1% terbinafine cream. Response and adverse effects were assessed at 2 and 4 weeks. Reduction in erythema, scaling, pruritus and clinical, and mycological cure constituted efficacy outcomes.ResultsThe mean duration of lesions was 2.82 ± 1.35 months. Complete clinical cure was observed in 50% and 48%, whereas mycological cure was attained in 56% and 52% patients in groups A and B, respectively, after 4 weeks, which was statistically insignificant. Reduction in erythema, scaling, and pruritus after 4 weeks when compared between the two groups, was also statistically insignificant.ConclusionSame class of oral and topical antifungal agents has comparable efficacy with different classes of oral and topical antifungal agents in dermatophyte infection.     

Treatment of toenail onychomycosis with oral terbinafine plus aggressive debridement: IRON-CLAD, a large, randomized, open-label, multicenter trial

This study was conducted to investigate the efficacy of oral terbinafine with and without aggressive debridement for the treatment of toenail onychomycosis. Onychomycosis patients aged 18 to 75 years received 12 weeks of terbinafine, 250 mg/day, alone (n = 255) or with aggressive debridement (n = 249). Both groups showed marked improvement from baseline at all time points. At week 48, complete, mycologic, and clinical cure rates were higher in the terbinafine plus debridement group compared with the terbinafine alone group, although significance was reached only for clinical cure (59.8% versus 51.4%; P = .023). Although approximately 39% of the patients received at least one antidiabetic, antihypertensive, or cholesterol-lowering agent concomitantly, including statins, the incidence of treatment-emergent adverse events was low and the adverse events were generally mild to moderate in severity. No clinically significant changes in liver transaminase levels were observed 6 weeks after treatment or after 12 weeks in those tested. These results support the well-established safety and efficacy of terbinafine for treatment of onychomycosis.     

特比萘芬治疗老年糖尿病患者趾甲真菌病疗效观察

目的观察应用时间对特比萘芬治疗趾甲真菌病的疗效和安全性。方法将84例老年糖尿病趾甲真菌病患者随机分为两组,均口服特比萘芬250mg／d,观察组共治疗16周,对照组12周。停药后24周观察疗效。结果观察组治愈率68．2％,高于对照组40．0％（x^2=6．71,P〈0．01）;观察组显效率为86．4％,高于对照组的67．5％（X^2=4．26,P〈0．05）。真菌治愈率观察组为93．2％,对照组为77．4％,观察组优于对照组（x^2=4．21,P〈0．05）。在停药52周时,观察组30例中复发2例,对照组16例中复发6例,差异有统计学意义（x^2=4．93,P〈0．05）。结论应用时间影响特比萘芬治疗趾甲真菌病的效果。应用时间长,治愈率高,复发率低。     

口服特比萘芬加外用益康唑短程联合疗法治疗足癣的临床对照研究

目的评价口服特比萘芬片加外用益康唑乳膏短程联合疗法治疗足癣的疗效和安全性。方法采用随机数字表法将124名患者分为两组：试验组予特比萘芬片250mg口服,1次／d,联合盎康唑乳膏外用,2次／d,共7d;对照组予益康唑乳膏外用,2次／d,同时口服维生索C片0．1g,1次／d,共28d。于停药时和停药后4周时观察临床疗效和真蔺学疗效,停药后4同时观察复发情况。结果共有113例患者完成临床观察．脱落7例（试验组1例,对照组6例）,剔除4例（对照组4例）。停药时两组相比试验组治愈率明显低于对照组（χ^2=23．03,P〈0．01）,有效率及真菌清除率差异无统计学意义（χ^2=0．33,P〉0．05;χ^2=0．03,P〉0．05）;停药后4周时两组相比试验组治愈率、有效率及真菌清除率均显著高于对照组（χ^2=17．21,P〈0．01;χ^2=14．56,P〈0．01;）（χ^2=23．03,P〈0．01）;停药后4周时两组相比试验组复发率明显低于对照组（χ^2=14．04,P〈0．01）;两组不良反应发生率相比差异无统计学意义（χ^2=3．27,P〉0．05）。结论口服特比萘芬片加外用益康唑乳膏短程联合疗法治疗足癣依从性和安全性高、疗效好。     

0.9 ms 1064 nm Nd：YAG激光联合伊曲康唑治疗趾甲真菌病

目的探究0.9 ms 1064 nm Nd：YAG激光联合伊曲康唑治疗趾甲真菌病的临床疗效及安全性。方法对37例（178个甲） 趾甲真菌病患者随机分为甲乙两组,再按甲真菌病临床评分指数（SCIO）和甲真菌病严重度指数（OSI）分值高低各分为不同亚 组。所有患者均使用激光治疗（1次/周,共8次）。乙组第1周口服伊曲康唑0.2 g,2/日。比较治疗前后的疗效、临床评分、外观变 化以及不良反应,并进行患者满意度调查。结果随访12个月,临床有效率甲组31.33%、乙组35.79%;真菌清除率甲组30.00%、 乙组41.18%;两组临床有效率、真菌清除率差异均无统计学意义（P>0.05）。SCIO/OSI变化,甲组均无统计学意义（P>0.05）、乙 组均有统计学意义（P<0.05）;SCIO<12、OSI<16时,不同亚组之间临床有效率无明显差异（P>0.05）;SCIO≥12、OSI≥16时,不同 亚组之间临床有效率有差异性（P<0.05）。分别有33.71%、74.72%、70.79%的病甲在面积、形状、颜色方面得到改善。62.16%患 者对治疗效果满意。所有患者无明显不良反应。结论0.9 ms 1064 nm Nd：YAG激光1年内有效改善甲真菌病病甲的外观,对 于较为严重的甲真菌病,联合伊曲康唑治疗是个更好的选择。     

三种常见抗真菌药口服治疗甲真菌病疗效观察

目的了解伊曲康唑、特比萘芬和氟康唑口服治疗甲真菌病的疗效。方法63例患者根据治疗药物的不同分为三组,伊曲康唑组41例,特比萘芬组13例,氟康唑组9例。分别在疗程结束后3个月和6个月时,进行真菌学检查和临床症状观察。结果伊曲康唑、特比萘芬和氟康唑治疗结束3个月和6个月的临床有效率分别为87．80％和92．68％、84．62％和92．31％、88．89％和88．89％;治疗结束3个月和6个月真菌学治愈率一致,分别为100％、92．31％和100％％。结论伊曲康唑与特比萘芬和氟康唑治疗甲真菌病均能取得较好的疗效。美扶因价格相对便宜,抗菌谱更广,具有更高的效价比。     

Efficacy of terbinafine for toenail onychomycosis. A multicenter trial of various treatment durations

The efficacy of terbinafine (250 mg/day) in the treatment of toenail onychomycosis was evaluated in a large open-label, multicenter trial of 12, 18, and 24 weeks of therapy. All 1,534 patients had onychomycosis, confirmed by either positive potassium hydroxide (KOH) wet mount, positive fungal culture, or both, and all received at least 12 weeks of treatment. Treatment was continued for an additional 6 or 12 weeks, depending on the extent of the disease at follow-up. Mycologic cure rates (negative culture plus negative KOH) at week 72 were 72.1% in the 12-week treatment group, 72.5% in the 18-week group, and 77.0% in the 24-week group. In all groups, clinical cure rates were higher at week 72 than at week 48: 49.5% of the 12-week group, 49.2% of the 18-week group, and 44.6% of the 24-week group experienced clinical cure by the end of the study. Both mycologic and clinical recurrence rates were low in all treatment groups at the 72-week assessment. The results of this study confirm the efficacy of terbinafine in the treatment of toenail onychomycosis as demonstrated in previous registration and large-scale clinical trials.     

伊曲康唑短期疗法治疗男性念珠菌性尿道炎34例临床分析

目的:探讨伊曲康唑口服短期疗法治疗男性念珠菌性尿道炎的疗效。方法:34例男性念珠菌性尿道炎患者给予伊曲康唑200 mg,2次/d,连服3d,停药2周后观察疗效。结果:临床疗效:治愈率85.3%,有效率97.0%;真菌学疗效:治愈率94.1%。结论:伊曲康唑3日疗法治疗男性念珠菌性尿道炎疗效高,疗程短,不良反应小,值得推广应用。     

特比萘芬联合半导体激光治疗甲癣102例疗效观察

目的 分析特比萘芬联合半导体激光治疗甲癣的临床疗效.方法 选取我科2011年3月至2015年3月门诊就诊的甲癣患者共102例.按照患者接受的治疗方案,分为联合组和对照组.对照组口服盐酸特比萘芬片0.25 g,1次/d,连服12周.联合组在对照组治疗方案基础上,加用半导体激光照射治疗,每周2次,疗程相同.停药24周后,对比两组患者的临床疗效.结果 与对照组比较,联合组治疗后病甲(指甲、趾甲)的指甲生长长度、甲分离、甲板增厚、甲板破坏程度和甲沟炎评分、甲真菌病临床评分指数差异有统计学意义(P＜0.05);联合组治疗后的总有效率、清除率高于对照组(100.00％ vs 90.19％,54.92％vs29.41％,P＜0.05).结论 特比萘芬联合半导体激光治疗甲癣具有较好的临床疗效.     

伊曲康唑冲击疗法治疗甲真菌病50例

目的： 评价伊曲康唑冲击疗法治疗由皮肤癣菌、酵母菌和霉菌引起的甲真菌病的有效性、安全性和耐受性。方法： 采用冲击疗法, 连续服用伊曲康唑（４００ ｍｇ／ｄ） １ 周后, 停药３周为１ 个疗程。指甲真菌病服药２ 个疗程; 趾甲真菌病服药３ 个疗程。观察疗程结束、停药３个月及停药６ 个月时指（ 趾） 甲真菌病的临床治愈率和真菌学治愈率。结果： 疗程结束时、停药后３ 个月及停药后６ 个月时指甲真菌病的临床治愈率分别为２５ ％ 、８５ ％ 和９０ ％ , 真菌学治愈率分别为６５ ％ 、９０ ％ 和９５ ％ ; 趾甲真菌病的临床治愈率分别为１６－６ ％ 、６３－３ ％ 和８６－７ ％ , 真菌学治愈率分别为５６－７ ％ 、８３－３ ％ 和９０ ％ 。疗程结束后, 随时间延长治愈率不断提高, 停药后６ 个月达最高。指甲真菌病的治愈率高于趾甲真菌病; 真菌学治愈率高于临床治愈率。未发现严重不良反应。停药后６ 个月时复发率为６ ％ 。结论： 伊曲康唑为广谱抗真菌药, 冲击疗法治疗甲真菌病具有疗效高、安全性好、耐受性高以及费用低廉的特点。     

伊曲康唑联合甲床修整术治疗重症甲真菌病的疗效观察

目的观察口服伊曲康唑联合甲床修整术治疗重症甲真菌病的临床疗效。方法将140例甲真菌病患者随机分为两组,治疗组68例采用甲床修整术联合口服伊曲康唑治疗;对照组72例单纯口服伊曲康唑治疗。结果治疗组痊愈率及总有效率分别为70.6%及88.2%,对照组分别为45.8%及65.2%,两组患者痊愈率及总有效率差异均有显著统计学意义（P〈0.01）。结论伊曲康唑口服联合甲床修整术治疗重症甲真菌病疗效高,能显著改善新甲的生长速度及外观。     

中药醋泡联合联苯苄唑乳膏治疗足癣疗效观察

将本院375例足癣患者,用随机表法随机分为治疗组（196例）和对照组（179例）,治疗组予中药醋泡联合1%联苯苄唑乳膏治疗,对照组仅外用1%联苯苄唑乳膏.以临床症状、体征评分及真菌学检测评估疗效,并记录不良反应.停药2周后,治疗组与对照组痊愈率分别为45.41%（89/196）和34.08%（61/179）,有效率分别为77.04%（151/196）和61.45%（110/179）,两组差异有统计学意义（P＜0.05）.两组真菌清除率和局部不良反应发生率的差异无统计学意义（P＞0.05）.     

伊曲康唑短程疗法治疗角化型手癣2种方案比较

目的：讨价并比较伊曲康唑２种短程疗法治疗角化型手癣的临床疗效、真菌学疗效及安全性。方法：将４５例患分为１周疗法组和２周疗法组。１周疗法组给予伊曲康唑２００ｍｇＢｉｄ,服用７ｄ;２周疗法组给予伊曲康唑２００ｍｇＱｄ,服用１４ｄ。在服药前及停药后第２周及第４周进行临床症状和体征观察及真菌学镜检及培养。在服药前及停药第４周时进行肝功能检查。以停药第４周时的结果作为观察疗效的标准。结果：１周疗法组在停药第４周时的临床痊愈率为８２．６％,总有效率为９５．６％,真菌学治愈率为９５．６％。２周疗法组在停药第４周时的临床痊愈率为８１．８％,总有效率为９０．９％,真菌学治愈率为９５．４％。２组间差异不显（Ｐ〉０．０５）。２组各有２例患出现轻度副作用,均未见严重不良反应。结论：伊曲康唑的２种短程疗法治疗角化型手癣均有效,且具     

Intermittent-pulse treatment of onychomycosis with orally administered itraconazole]

Fifty-four patients received an intermittent regimen of itraconazole (26 of them were finger onychomycosis and 28 toe onychomycosis) and were followed-up for nine months. The result showed that the clinical cure rate of fingernails was 88.5% and the mycologic cure rate was 96.4%, while the clinical cure rate of toes was 82.1% and the mycologic cure rate was 96.4%. Few adverse events were observed by 7.4%, just like nausea, gastric discomfort etc. It suggests that the pulse administration system is highly effective and has a few side-effects.     

长脉宽1064 nm Nd：YAG激光治疗趾甲真菌病的疗效及安全性

目的：探讨长脉宽1064 nm Nd：YAG激光治疗趾甲真菌病的疗效及安全性。方法对确诊的104例（461个趾甲）趾甲真菌病患者,根据年龄段分为Ⅰ组（≥60岁）和Ⅱ组（<60岁）,按照SCIO评分及病甲位置的差异分为不同亚组;所有患者病甲均使用长脉宽1064 nm Nd：YAG激光进行每周1次、共10~12次的治疗,随访至初次治疗后的48周,观察疗效及不良反应。结果所有病人随访至48周,总体临床有效率为72.5%。Ⅱ组的临床有效率和真菌学治愈率均高于Ⅰ组,差异有统计学意义（P<0.05）。不同SCIO亚组之间的临床有效率无统计学差异（P>0.05）。第2~4趾甲亚组的临床有效率优于第1、第5趾甲亚组,差异有统计学意义（P<0.05）;所有患者无明显不良反应。结论长脉宽1064 nm Nd：YAG激光是一种安全微创有效的治疗甲真菌病的方法,可在临床推广使用。     

Treatment of dermatophyte toenail onychomycosis in the United States. A pharmacoeconomic analysis

This study attempted to determine the cost-effectiveness of therapies for dermatophyte toenail onychomycosis in the United States in 2001. The antimycotic agents evaluated were ciclopirox 8% nail lacquer and the oral agents terbinafine, itraconazole (pulse), itraconazole (continuous), fluconazole, and griseofulvin. A treatment algorithm for the management of onychomycosis was developed, and a meta-analysis was carried out to determine the average mycologic and clinical response rates for the various agents. The cost of the regimen was figured as the sum of the costs of drug acquisition, medical management, and management of adverse effects. The expected cost of management and disease-free days were determined, and a sensitivity analysis was conducted. It was concluded that ciclopirox 8% nail lacquer, which has recently become available in the larger size of 6.6 mL, is a cost-effective agent for the management of toenail onychomycosis.     

Satisfaction with onychomycosis treatment. Pulse versus continuous dosing

The purpose of this study, which involved two dermatology clinics and two podiatric medical clinics, was to determine whether a difference exists in patient-reported satisfaction and compliance between continuous terbinafine therapy and pulse-dose itraconazole therapy for the treatment of toenail onychomycosis. Patients in this multicenter, open-label, cross-sectional study had previously completed treatment with either oral terbinafine or oral itraconazole for toenail onychomycosis. Patients were interviewed by telephone to assess clinical outcomes, compliance, and satisfaction with treatment; clinical data were collected by medical chart review. Patients reported significantly greater ease and convenience of treatment and higher overall satisfaction with continuous terbinafine therapy compared with pulse-dose itraconazole therapy.     

护理干预对激光治疗灰指甲效果的影响

目的探讨护理干预对激光治疗灰指甲效果的影响。方法选取2011年7月至2012年9月我院收治的62例灰指甲患者,随机将其分为治疗组和对照组各31例,两组均采用激光治疗,对照组采用常规护理,治疗组在常规护理基础上实施整体护理干预方案。比较两组的疗效、不良反应和患者的满意度。结果治疗组总有效率为90.3%,高于对照组的77.4%,差异具有统计学意义（P〈0.05）;治疗组不良反应发生率为12.9%,明显低于对照组的58.1%,差异具有统计学意义（P〈0.05）;治疗组总满意率为87.1%,明显高于对照组的67.7%,差异具有统计学意义（P〈0.05）。结论整体护理干预可以有效提高激光治疗灰指甲的疗效,降低不良反应的发生率,提高患者的满意度。     

特比奈芬治疗88例儿童甲真菌病临床观察

目的 观察特比奈芬治疗儿童甲真菌病的疗效及安全性。方法 应用特比奈芬治疗儿童指甲真菌病50例及趾甲真菌病38例，并作疗效、真菌清除率及安全性观察。结果 特比奈芬治疗儿童指甲真菌病的痊愈率及总有效率分别为92．1％和97-37％：趾甲真菌病则分别为86．36％和93．94％。真菌清除率均达到96．59％。在本临床研究中未发现特比奈芬有严重的毒副反应。结论 特比奈芬治疗儿童甲真菌病疗效显著、安全性高，是有效根治儿童甲真菌病的方法之一。     

特比奈芬治疗88例儿童甲真菌病临床观察

目的 观察特比奈芬治疗儿童甲真菌病的疗效及安全性.方法 应用特比奈芬治疗儿童指甲真菌病50例及趾甲真菌病38例,并作疗效、真菌清除率及安全性观察.结果 特比奈芬治疗儿童指甲真菌病的痊愈率及总有效率分别为9.1%和97.37%;趾甲真菌病则分别为86.36%和93.94%.真菌清除率均达到96.59%.在本临床研究中未发现特比奈芬有严重的毒副反应.结论 特比奈芬治疗儿童甲真菌病疗效显著、安全性高,是有效根治儿童甲真菌病的方法之一.